Home >  Registry
     
 
Protocol Registry Trial Results IFPMA Background Links
About this Registry

This registry serves as a global repository for information on ongoing Roche Pharmaceuticals Phase II to Phase IV clinical studies, Phase I studies in patients and Roche Diagnostics interventional studies on advanced diagnostic products.

For More Information 

Common Questions
More Frequently Asked Questions 
Overview of Clinical Trials 
Glossary of Terms 
Phase Definitions 
Field Definitions 
Roche Clinical Trial Global Policy 
Site Provided by Thomson CenterWatch

Trial information

A Study of Tarceva (Erlotinib) Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Status: Recruiting

Protocol number: ML17915

Sponsor: Roche Farma S.A.

Company division: Pharmaceutical

Official Scientific Title: An open-label study of the effect of Tarceva monotherapy on treatment response in patients with advanced non-small cell lung cancer for whom Tarceva monotherapy is considered the best option

Brief summary: This study will evaluate the efficacy and safety of oral Tarceva in patients with advanced NSCLC for whom Tarceva monotherapy is considered the best therapeutic option. The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals. Target sample size is 1049.

Study phase: II

Study type: Interventional; Treatment; Non-Randomized; Open Label; Uncontrolled; Parallel; Safety/Efficacy study

Condition: Non-Small Cell Lung Cancer

Intervention type: Drug

Intervention name: erlotinib[Tarceva]

Primary outcome: 1. Efficacy: Clinical benefit (time to progression).

Key secondary outcomes: 1. Efficacy: Rates of partial response, complete response, and stable disease. Overall survival. Safety: Adverse events

Inclusion criteria:

  • adult patients >=18 years of age;
  • locally advanced or metastatic NSCLC (Stage IIIB or IV);
  • not a candidate for curative surgery or radical chemotherapy;
  • no brain metastases, or clinically stable metastases for >=2 months.

Exclusion criteria:

  • radiotherapy over the previous 2 weeks;
  • weight loss >10% in the previous 6 weeks.

Gender: Males or Females

Age limits: Min: 18 Years Max: N/A (No limit)

Accepts healthy volunteers: No

Anticipated start date: April, 2004

Trial registration date: 11/01/2005

Date last updated: 9/29/2008


Link to trial result

This trial is being conducted at the following locations:

Spain

  • Alcorcon
  • Alcoy
  • Algeciras
  • Alicante
  • Almería
  • Avila
  • Badajoz
  • Badalona
  • Barakaldo
  • Barcelona
  • Baza
  • Bilbao
  • Burgos
  • Cádiz
  • Castellon
  • Córdoba
  • Don Benito
  • El Palmar Murcia
  • Elche
  • Ferrol
  • Girona
  • Granada
  • Granollers
  • Huelva
  • Ibiza
  • Jaen
  • La Coruna
  • La Laguna
  • Las Palmas de Gran Canaria
  • Leon
  • Lleida
  • Lugo
  • Madrid
  • Malaga
  • Manresa
  • Mataro
  • Merida
  • Murcia
  • Navarra
  • Orense
  • Palencia
  • Palma de Mallorca
  • Pamplona
  • Sabadell
  • Sagunto
  • Salamanca
  • San Sebastian
  • Sant Coloma Gramenet
  • Sant Pere De Ribes
  • Santa Cruz de Tenerife
  • Santander
  • Segovia
  • Sevilla
  • Terrassa
  • Torrevieja
  • Valencia
  • Valladolid
  • Vic
  • Vigo
  • Zaragoza

To contact Roche for more information on this trial please complete the email form below. Treatment decisions and/or suitability for a specific trial are decisions only your healthcare provider can make. If you are patient interested in any of the studies, please have your healthcare provider contact us via this website, and they will be provided with the relevant clinical trial information.

Country*
Are you a:*
Subject*
Last Name*
First Name*
Telephone
E-mail*

your email address is needed for us to reply